Clinical trial
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
NCT00273312 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00273312 |
|---|---|
| Title | Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma |
| Official title | An Open-label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Patupilone |
| Enrollment | 25 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2006 |
| First posted | Jan 9, 2006 |
| Last update posted | Feb 7, 2017 |
| Countries | Hong Kong, South Korea, Taiwan, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: